Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

A Cost-Utility Analysis of Cryoballoon Ablation versus Radiofrequency Ablation for Paroxysmal Atrial Fibrillation.

Murray MI, Bonet MJ, Naci H, Zeiher AM.

J Atr Fibrillation. 2018 Dec 31;11(4):2069. doi: 10.4022/jafib.2069. eCollection 2018 Dec.

2.

Cyprus Women's Health Research (COHERE) initiative: determining the relative burden of women's health conditions and related co-morbidities in an Eastern Mediterranean population.

Hocaoglu MB, Gurkas S, Karaderi T, Taneri B, Erguler K, Barin B, Bilgin EM, Eralp G, Allison M, Findikli N, Boynukalin K, Bahceci M, Naci H, Vincent K, Missmer SA, Becker CM, Zondervan KT, Rahmioglu N.

BMC Womens Health. 2019 Apr 3;19(1):50. doi: 10.1186/s12905-019-0750-1. No abstract available.

3.

Combining Multiple Treatment Comparisons with Personalized Patient Preferences: A Randomized Trial of an Interactive Platform for Statin Treatment Selection.

Hopkin G, Au A, Collier VJ, Yudkin JS, Basu S, Naci H.

Med Decis Making. 2019 Apr;39(3):264-277. doi: 10.1177/0272989X19835239. Epub 2019 Mar 15.

PMID:
30873906
4.

Personalizing Second-Line Type 2 Diabetes Treatment Selection: Combining Network Meta-analysis, Individualized Risk, and Patient Preferences for Unified Decision Support.

Choi SE, Berkowitz SA, Yudkin JS, Naci H, Basu S.

Med Decis Making. 2019 Apr;39(3):239-252. doi: 10.1177/0272989X19829735. Epub 2019 Feb 15.

PMID:
30767632
5.

New agreement on branded drugs for the NHS.

Naci H, Dixon J.

BMJ. 2019 Jan 18;364:l266. doi: 10.1136/bmj.l266. No abstract available.

PMID:
30658964
6.

How does exercise treatment compare with antihypertensive medications? A network meta-analysis of 391 randomised controlled trials assessing exercise and medication effects on systolic blood pressure.

Naci H, Salcher-Konrad M, Dias S, Blum MR, Sahoo SA, Nunan D, Ioannidis JPA.

Br J Sports Med. 2018 Dec 18. pii: bjsports-2018-099921. doi: 10.1136/bjsports-2018-099921. [Epub ahead of print] Review.

PMID:
30563873
7.

Assessment of Devices, Diagnostics and Digital Technologies: A Review of NICE Medical Technologies Guidance.

Crispi F, Naci H, Barkauskaite E, Osipenko L, Mossialos E.

Appl Health Econ Health Policy. 2019 Apr;17(2):189-211. doi: 10.1007/s40258-018-0438-y.

PMID:
30367349
8.

A review of NICE appraisals of pharmaceuticals 2000-2016 found variation in establishing comparative clinical effectiveness.

Anderson M, Naci H, Morrison D, Osipenko L, Mossialos E.

J Clin Epidemiol. 2019 Jan;105:50-59. doi: 10.1016/j.jclinepi.2018.09.003. Epub 2018 Sep 18. Review.

PMID:
30236484
9.

Planning a future randomized clinical trial based on a network of relevant past trials.

Salanti G, Nikolakopoulou A, Sutton AJ, Reichenbach S, Trelle S, Naci H, Egger M.

Trials. 2018 Jul 11;19(1):365. doi: 10.1186/s13063-018-2740-2.

10.

The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.

Wallach JD, Ross JS, Naci H.

Clin Trials. 2018 Jun;15(3):219-229. doi: 10.1177/1740774518770648.

PMID:
29871509
11.

The US Food and Drug Administration's expedited approval programs: Addressing premarket flexibility with enhanced postmarket evidence generation.

Wallach JD, Ross JS, Naci H.

Clin Trials. 2018 Jun;15(3):243-246. doi: 10.1177/1740774518770657. No abstract available.

PMID:
29871507
12.

Evidence Required for Drugs Granted Accelerated Approval-Reply.

Naci H, Kesselheim AS.

JAMA. 2017 Dec 26;318(24):2493-2494. doi: 10.1001/jama.2017.17184. No abstract available.

PMID:
29279923
13.

Training the next generation of cardiovascular leaders in health policy and economics.

Naci H, Kirchhof P, Vahanian A, Steffel J, Bardinet I, Mossialos E, Vardas P.

Eur Heart J. 2017 Dec 1;38(45):3332-3335. doi: 10.1093/eurheartj/ehx673. No abstract available.

PMID:
29206965
14.

Accelerated access to new drugs and technologies.

Naci H, Mossialos E.

BMJ. 2017 Nov 22;359:j5387. doi: 10.1136/bmj.j5387. No abstract available.

PMID:
29167095
15.
16.

Evolocumab in Patients with Cardiovascular Disease.

Naci H, Mehra MR.

N Engl J Med. 2017 Aug 24;377(8):785-6. doi: 10.1056/NEJMc1708587. No abstract available.

PMID:
28836419
17.

Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration.

Naci H, Smalley KR, Kesselheim AS.

JAMA. 2017 Aug 15;318(7):626-636. doi: 10.1001/jama.2017.9415.

18.

Health policy in times of austerity-A conceptual framework for evaluating effects of policy on efficiency and equity illustrated with examples from Europe since 2008.

Wenzl M, Naci H, Mossialos E.

Health Policy. 2017 Sep;121(9):947-954. doi: 10.1016/j.healthpol.2017.07.005. Epub 2017 Jul 19.

19.

Impact of the International Recommendations for Electrocardiographic Interpretation on Cardiovascular Screening in Young Athletes.

Dhutia H, Malhotra A, Finocchiaro G, Merghani A, Papadakis M, Naci H, Tome M, Sharma S.

J Am Coll Cardiol. 2017 Aug 8;70(6):805-807. doi: 10.1016/j.jacc.2017.06.018. No abstract available.

20.

What to do (or not to do) when randomization is not possible.

Naci H.

J Heart Lung Transplant. 2017 Nov;36(11):1174-1177. doi: 10.1016/j.healun.2017.07.008. Epub 2017 Jul 17. No abstract available.

PMID:
28756119
21.

Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval.

Naci H, Wouters OJ, Gupta R, Ioannidis JPA.

Milbank Q. 2017 Jun;95(2):261-290. doi: 10.1111/1468-0009.12261.

22.

Avoidable costs of stenting for aortic coarctation in the United Kingdom: an economic model.

Salcher M, Mcguire A, Muthurangu V, Kelm M, Kuehne T, Naci H; CARDIOPROOF.

BMC Health Serv Res. 2017 Apr 10;17(1):258. doi: 10.1186/s12913-017-2215-2.

23.

The impact of post-procedural complications on reimbursement, length of stay and mechanical ventilation among patients undergoing transcatheter aortic valve implantation in Germany.

Kaier K, Reinecke H, Naci H, Frankenstein L, Bode M, Vach W, Hehn P, Zirlik A, Zehender M, Reinöhl J.

Eur J Health Econ. 2018 Mar;19(2):223-228. doi: 10.1007/s10198-017-0877-7. Epub 2017 Feb 22.

PMID:
28229254
24.

Bicuspid aortic valve disease: systematic review and meta-analysis of surgical aortic valve repair.

Salcher M, Naci H, Pender S, Kuehne T; CARDIOPROOF Consortium, Kelm M.

Open Heart. 2016 Dec 16;3(2):e000502. doi: 10.1136/openhrt-2016-000502. eCollection 2016.

25.

Communication of Treatment Rankings Obtained From Network Meta-Analysis Using Data Visualization.

Naci H.

Circ Cardiovasc Qual Outcomes. 2016 Sep;9(5):605-8. doi: 10.1161/CIRCOUTCOMES.116.002874. Epub 2016 Sep 6. No abstract available.

PMID:
27601459
26.

Cost Implications of Using Different ECG Criteria for Screening Young Athletes in the United Kingdom.

Dhutia H, Malhotra A, Gabus V, Merghani A, Finocchiaro G, Millar L, Narain R, Papadakis M, Naci H, Tome M, Sharma S.

J Am Coll Cardiol. 2016 Aug 16;68(7):702-11. doi: 10.1016/j.jacc.2016.05.076.

27.

History Bias, Study Design, and the Unfulfilled Promise of Pay-for-Performance Policies in Health Care.

Naci H, Soumerai SB.

Prev Chronic Dis. 2016 Jun 23;13:E82. doi: 10.5888/pcd13.160133. No abstract available.

28.

Balloon Dilatation and Stenting for Aortic Coarctation: A Systematic Review and Meta-Analysis.

Salcher M, Naci H, Law TJ, Kuehne T, Schubert S, Kelm M; Cardioproof Consortium.

Circ Cardiovasc Interv. 2016 Jun;9(6). pii: e003153. doi: 10.1161/CIRCINTERVENTIONS.115.003153. Review.

PMID:
27296199
29.

Economic evaluation of mental health interventions: an introduction to cost-utility analysis.

Luyten J, Naci H, Knapp M.

Evid Based Ment Health. 2016 May;19(2):49-53. doi: 10.1136/eb-2016-102354. Epub 2016 Apr 13. Review.

PMID:
27075444
30.

Preventing cardiovascular events with empagliflozin: at what cost?

Naci H, Basu S, Yudkin JS.

Lancet Diabetes Endocrinol. 2015 Dec;3(12):931. doi: 10.1016/S2213-8587(15)00439-8. No abstract available.

PMID:
26590682
31.

Timely publication and sharing of trial data: opportunities and challenges for comparative effectiveness research in cardiovascular disease.

Naci H, Cooper J, Mossialos E.

Eur Heart J Qual Care Clin Outcomes. 2015 Nov 1;1(2):58-65. doi: 10.1093/ehjqcco/qcv012.

PMID:
29474595
32.

Why the drug development pipeline is not delivering better medicines.

Naci H, Carter AW, Mossialos E.

BMJ. 2015 Oct 23;351:h5542. doi: 10.1136/bmj.h5542. No abstract available.

33.

Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study.

Naci H, Ioannidis JP.

Br J Sports Med. 2015 Nov;49(21):1414-22. doi: 10.1136/bjsports-2015-f5577rep. Review.

34.

Rethinking the appraisal and approval of drugs for type 2 diabetes.

Naci H, Lehman R, Wouters OJ, Goldacre B, Yudkin JS.

BMJ. 2015 Oct 9;351:h5260. doi: 10.1136/bmj.h5260. Review. No abstract available.

PMID:
26452524
35.

QALYs in cost-effectiveness analysis: an overview for cardiologists.

Wouters OJ, Naci H, Samani NJ.

Heart. 2015 Dec;101(23):1868-73. doi: 10.1136/heartjnl-2015-308255. Epub 2015 Sep 22. Review.

PMID:
26395316
36.

Correction: An Assessment of the Methodological Quality of Published Network Meta-Analyses: A Systematic Review.

Chambers JD, Naci H, Wouters OJ, Pyo J, Gunjal S, Kennedy IR, Hoey MG, Winn A, Neumann PJ.

PLoS One. 2015 Jul 21;10(7):e0131953. doi: 10.1371/journal.pone.0131953. eCollection 2015.

37.

Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology.

Jackson N, Atar D, Borentain M, Breithardt G, van Eickels M, Endres M, Fraass U, Friede T, Hannachi H, Janmohamed S, Kreuzer J, Landray M, Lautsch D, Le Floch C, Mol P, Naci H, Samani NJ, Svensson A, Thorstensen C, Tijssen J, Vandzhura V, Zalewski A, Kirchhof P.

Eur Heart J. 2016 Mar 1;37(9):747-54. doi: 10.1093/eurheartj/ehv213. Epub 2015 Jun 15. Review.

PMID:
26077039
38.

Evaluation of Wellness Determinants and Interventions by Citizen Scientists.

Naci H, Ioannidis JP.

JAMA. 2015 Jul 14;314(2):121-2. doi: 10.1001/jama.2015.6160. No abstract available.

PMID:
26068643
39.

Applying Multiple Criteria Decision Analysis to Comparative Benefit-Risk Assessment: Choosing among Statins in Primary Prevention.

Tervonen T, Naci H, van Valkenhoef G, Ades AE, Angelis A, Hillege HL, Postmus D.

Med Decis Making. 2015 Oct;35(7):859-71. doi: 10.1177/0272989X15587005. Epub 2015 May 18.

PMID:
25986470
40.

An assessment of the methodological quality of published network meta-analyses: a systematic review.

Chambers JD, Naci H, Wouters OJ, Pyo J, Gunjal S, Kennedy IR, Hoey MG, Winn A, Neumann PJ.

PLoS One. 2015 Apr 29;10(4):e0121715. doi: 10.1371/journal.pone.0121715. eCollection 2015. Review. Erratum in: PLoS One. 2015;10(7):e0131953.

41.

From "retailers" to health care providers: Transforming the role of community pharmacists in chronic disease management.

Mossialos E, Courtin E, Naci H, Benrimoj S, Bouvy M, Farris K, Noyce P, Sketris I.

Health Policy. 2015 May;119(5):628-39. doi: 10.1016/j.healthpol.2015.02.007. Epub 2015 Feb 18.

PMID:
25747809
42.

Capsule commentary on Ott et al., do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials.

Naci H.

J Gen Intern Med. 2015 Mar;30(3):347. doi: 10.1007/s11606-014-3158-5. No abstract available.

43.

No evidence of industry sponsorship bias in statin trials.

Naci H, Dias S, Ades T.

BMJ. 2014 Nov 4;349:g6579. doi: 10.1136/bmj.g6579. No abstract available.

PMID:
25371223
44.
45.

How good is "evidence" from clinical studies of drug effects and why might such evidence fail in the prediction of the clinical utility of drugs?

Naci H, Ioannidis JP.

Annu Rev Pharmacol Toxicol. 2015;55:169-89. doi: 10.1146/annurev-pharmtox-010814-124614. Epub 2014 Aug 21.

PMID:
25149917
46.

Persistent medication affordability problems among disabled Medicare beneficiaries after Part D, 2006-2011.

Naci H, Soumerai SB, Ross-Degnan D, Zhang F, Briesacher BA, Gurwitz JH, Madden JM.

Med Care. 2014 Nov;52(11):951-6. doi: 10.1097/MLR.0000000000000205.

47.

Evidence-based prescribing: combining network meta-analysis with multicriteria decision analysis to choose among multiple drugs.

Naci H, van Valkenhoef G, Higgins JP, Fleurence R, Ades AE.

Circ Cardiovasc Qual Outcomes. 2014 Sep;7(5):787-92. doi: 10.1161/CIRCOUTCOMES.114.000825. Epub 2014 Aug 5. Review. No abstract available.

PMID:
25097214
48.

Medication affordability gains following Medicare Part D are eroding among elderly with multiple chronic conditions.

Naci H, Soumerai SB, Ross-Degnan D, Zhang F, Briesacher BA, Gurwitz JH, Madden JM.

Health Aff (Millwood). 2014 Aug;33(8):1435-43. doi: 10.1377/hlthaff.2013.1067.

49.

Regulators should better leverage effectiveness standards to enhance drug value.

Naci H, Alexander GC.

Pharmacotherapy. 2014 Oct;34(10):1005-11. doi: 10.1002/phar.1467. Epub 2014 Jul 19. Review.

PMID:
25041851
50.

Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study.

Naci H, Ioannidis JP.

BMJ. 2013 Oct 1;347:f5577. doi: 10.1136/bmj.f5577. Review.

Supplemental Content

Support Center